Blue Horseshoe Stocks: INFI Review & More

Infinity Pharmaceuticals, Inc. INFI

The stock with the most notable performance from yesterday morning’s watchlist was definitely INFI, which began trending up in the premarket, and continued its climb throughout the entire session.

The stock traded up from a low of 2.44 to 3.75, which works out to an intraday rise of 54% and it came on roughly 38X its monthly average volume. An early pullback from profit taking this morning would be a likely scenario, but if INFI can find support at a higher point than yesterday’s low, from



AcelRx Pharmaceuticals, Inc. ACRX

After the FDA’s rejecion of the company’s ‘Dsuvia” opioid painkiller, ACRX took a monstrous pounding yesterday down to its lowest price in three months.

As you can see on the chart, it fell all the way down to an area of support it had established back in July. We’ll be interested to monitor this play for a bottom, which could come at any time. Moves generated by FDA news, whether positive or negative, tend to be over-exaggerated and are almost always followed by a course correction.


Inotek Pharmaceuticals Corp ITEK

Here we have an example of being extremely ‘early to the party’ as we sometimes say. We alerted on ITEK back in July, after which point it saw a low of .89. It mostly traded sideways throughout the remainder of the summer, but recently began quite an impressive climb.

This morning, the stock hit news highs of 4.15 in premarket trading on news of a proposed merger with a clinical stage gene therapy company. It may have took a few months to realize, but it works out to an increase of 366%

For an added angle going forward, we’ll also signal the ITEK 10/20 $2.50 Calls for possible daytrades and/or swing trades into next week, and the 11/17 $2.50 & $5.00 Calls for a longer term idea.


Extended Watchlist:
SONS, MARK, HSC, DPW, AKS, CLF, RIG, ATNM, MGEN

Comments are closed.